Publication | Closed Access

The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

Hematological MalignancyLymphoid NeoplasiaRadiation OncologyCell TherapyTransplantationMarrow TransplantationMantle Cell LymphomaMedicineImmunologyHematologyExcellent Event-free SurvivalHyper-cvad–rituximab Chemotherapy ProgrammeImmunotherapyOncologyCell TransplantationHealth Sciences